Arkk Tdoc TDOC Stock Performance and Outlook

TDOC stock has been on a roll, with its value increasing by over 100% in the past year alone. This impressive growth can be attributed to the company's innovative approach to telemedicine.

As a leader in the digital health space, Teladoc Health (TDOC) has been at the forefront of the telemedicine revolution. Its platform offers convenient and affordable access to healthcare services, making it a go-to solution for patients and healthcare providers alike.

With a strong track record of success, TDOC's stock has been attracting investors looking for a piece of the action. Its market capitalization has increased significantly, making it one of the largest players in the telemedicine industry.

TDOC's growth prospects look promising, with the global telemedicine market expected to reach $186 billion by 2026.

On a similar theme: Arkk Forecast

Ark Invest has been loading up on Teladoc, with four of its exchange-traded funds buying shares in September.

Teladoc Health is now the seventh-largest holding for Wood's Ark Genomic Revolution ETF.

Ark Innovation ETF and Ark Genomic Revolution ETF increased their positions in Teladoc over the last couple of weeks.

Teladoc is the 16th-largest holding for both Ark Innovation ETF and Ark Next Generation Internet ETF.

Ark Fintech Innovation ETF also holds Teladoc, ranking it as its 21st-largest holding.

Teladoc is now Ark Invest's largest holding across all of its ETFs, with a 6.53% weighting and market value of about $1.5 billion.

Cathie Wood has been a longtime fan of Teladoc Health, first initiating a position in the stock way back in 2017.

Shares of TDOC have declined by more than 55% year-to-date, with the company's stock price currently trading just below $40.

The COVID-19 shutdowns in 2020 created surging demand for Teladoc's virtual care services, but the stock has been on a downhill ride for investors since early 2021.

Teladoc's services could gain popularity with the rise of monkeypox cases, as the White House has officially declared the disease a public health emergency.

In 2023, Teladoc stock has soared more than 25% a couple of times only to give up all of its gains, and is currently down nearly 30% year to date.

Vanguard is the second-largest shareholder of TDOC, with a stake of 13.32 million shares as of Q1, but Ark Invest now owns a total of 30.6 million shares, making it the largest shareholder by a wide margin.

Take a look at this: Ark Funds Stock